文献速递妇科

贝伐珠单抗跨线治疗:卵巢癌、输卵管癌和腹膜癌进展后再次贝伐珠单抗治疗的影响

Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
PubMed 文献 · Gynecol Oncol · 2025-02-22

多机构回顾性研究比较高级别非黏液性上皮性卵巢癌、输卵管癌和原发腹膜癌患者在接受含贝伐珠单抗方案进展后,立即再次使用含贝伐珠单抗方案与改用不含贝伐珠单抗方案(或不治疗)的生存差异。结果显示序贯贝伐珠单抗再治疗组中位无进展生存期和总生存期均显著延长。

要点

  • 序贯贝伐珠单抗再治疗组中位无进展生存期17.2个月,对照组5.1个月(p<0.001)。
  • 序贯再治疗组中位总生存期29.9个月,未再治疗组12.4个月(p<0.001)。
  • 全组中位随访17.3个月(范围1.2-138.2个月)。

核心结论

  • 卵巢癌患者在疾病进展时序贯使用含贝伐珠单抗方案再治疗,较未再使用贝伐珠单抗者生存期延长。

研究设计与样本

  • 多机构回顾性研究,纳入226例接受含贝伐珠单抗方案的高级别非黏液性上皮性卵巢癌、输卵管癌和原发腹膜癌患者。
  • 103例在进展时接受序贯含贝伐珠单抗再治疗,123例接受含贝伐珠单抗方案后改用不含贝伐珠单抗方案或不治疗。
  • 采用Kaplan-Meier法和Cox比例风险回归模型估计无进展生存期和总生存期。

主要发现

  • 全组中位随访17.3个月(范围1.2-138.2个月)。
  • 序贯贝伐珠单抗再治疗组中位无进展生存期17.2个月(95%CI 14.3-21.2),未再使用贝伐珠单抗组5.1个月(95%CI 4.3-6.3),p<0.001。
  • 序贯贝伐珠单抗再治疗组中位总生存期29.9个月(95%CI 26.1-35.4),未再使用贝伐珠单抗组12.4个月(95%CI 9.2-16.7),p<0.001。

临床怎么用

  • 原文未据此给出推荐,仅报告序贯贝伐珠单抗再治疗与生存期延长的相关性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluated whether patients with epithelial ovarian, fallopian tube, and primary peritoneal carcinoma (OC) who are immediately re-treated with bevacizumab derive benefit after disease progression on a bevacizumab-containing regimen. METHODS: This multi-institutional, retrospective study compared patients with high grade non-mucinous epithelial OC who received bevacizumab followed directly by another bevacizumab-containing treatment regimen to patients who received bevacizumab followed by a regimen that did not contain bevacizumab (or received no further treatment). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan Meier product-limit estimator and modeled via Cox proportional hazards regression. RESULTS: Among 226 patients with OC who received bevacizumab as part of a treatment regimen,103 received sequential treatment with bevacizumab and 123 received a bevacizumab-containing regimen followed by a non-bevacizumab-containing regimen at the time of progression. Median follow-up for all subjects was 17.3 months (range, 1.2-138.2 months). Median PFS was 17.2 months (95 % CI, 14.3-21.2) for patients who received sequential bevacizumab re-treatment and 5.1 months (95 % CI, 4.3-6.3) for patients who received bevacizumab without bevacizumab-containing re-treatment (p < 0.001). Median OS was 29.9 months (95 % CI, 26.1-35.4) for patients who received sequential bevacizumab re-treatment (p < 0.001) and 12.4 months (95 % CI, 9.2-16.7) for patients who did not receive bevacizumab-containing re-treatment. CONCLUSION: Patients with OC treated with bevacizumab-containing regimens sequentially at the time of progression have prolonged survival compared to patients who received no re-treatment with bevacizumab.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Asare A, Previs RA, Spinosa D, et al. Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression. Gynecol Oncol. 2025. PMID: 39987772. doi:10.1016/j.ygyno.2025.02.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。